Diffusing alpha-emitter radiation therapy with enhanced beta treatment

Patent metadata

Field	Value
Publication number	US-12246191-B2
Application number	US-202318480545-A
Country	US
Kind code	B2
Filing date	Oct 4, 2023
Priority date	Dec 16, 2020
Publication date	Mar 11, 2025
Grant date	Mar 11, 2025

Abstract

An interstitial source including a base suitable for implanting in a tumor and radioactive atoms of one or more isotopes, which are attached to the base. The radioactive atoms have a radon release rate of at least 0.5 micro-Curie (μCi) per centimeter length, and emit beta radiation achieving at 2 millimeters from the base an asymptotic dose of at least 10 Gy. Additionally, the ratio between the beta radiation asymptotic dose at a distance of 2 millimeters from the device, to the radon release rate, is greater than 15 Gy/(microcurie/cm).

First claim

The invention claimed is:

1. An interstitial source, comprising:
a base suitable for implanting in a tumor; and
radioactive atoms of one or more isotopes, which are attached to the base, wherein the radioactive atoms have a radon release rate of at least 0.5 micro-Curie (μCi) per centimeter length, and emit beta radiation achieving at 2 millimeters from the base an asymptotic dose of at least 10 Gy,
wherein the ratio between the beta radiation asymptotic dose at a distance of 2 millimeters from the device interstitial source, to the radon release rate, is greater than 15 Gy/(μCi/cm).

2. The source of claim 1 , wherein the ratio between the asymptotic dose at a distance of 2 millimeters from the interstitial source, to the radon release rate, is greater than 20 Gy/(μCi/cm).

3. The source of claim 1 , wherein the radioactive atoms comprise radium-224 atoms.

4. The source of claim 3 , wherein the radium-224 atoms have an activity of at least 1 μCi/cm.

5. The source of claim 4 , wherein the radium-224 atoms have an activity of at least 10.5 μCi/cm.

6. The source of claim 1 , wherein the radioactive atoms of one or more isotopes include one or more isotopes which do not emit alpha radiation, which emit beta radiation achieving at 2 millimeters from the base an asymptotic dose of at least 5 Gy.

7. The source of claim 1 , wherein the radioactive atoms are attached to the base with a desorption probability upon radioactive decay of not more than 30%.

8. The source of claim 1 , wherein the radioactive atoms attached to the base include at least 10.5 μCi per centimeter length of the base.

9. The source of claim 1 , wherein the radioactive atoms have a desorption probability upon decay of at least 2%.

10. The source of claim 1 , wherein the radioactive atoms are attached to the base with a desorption probability of less than 24%.

11. The source of claim 10 , wherein the radioactive atoms are attached to the base with a desorption probability of less than 20%.

12. The source of claim 11 , wherein the radioactive atoms are attached to the base by a heat treatment.

13. The source of claim 12 , wherein the radioactive atoms are attached to the base with a desorption probability of less than 15%.

14. The source of claim 1 , and further comprising a coating of a low-diffusion polymer covering the radioactive atoms in a manner which reduces a desorption probability of daughter radionuclides.

15. The source of claim 14 , wherein the coating has a thickness of at least 0.5 microns.

16. The source of claim 14 , wherein the coating comprises a non-metallic coating.

17. The source of claim 1 , and further comprising an atomic layer deposition coating of aluminum oxide covering the radioactive atoms.

18. The source of claim 17 , wherein the atomic layer deposition coating has a thickness of at least 2 nanometers.

19. The source of claim 1 , wherein at least 90% of the beta radiation is emitted from progeny of alpha emitting atoms.

20. The source of claim 19 , wherein at least 20% of the beta radiation is emitted from an isotope which does not emit alpha radiation.

Assignees

• Alpha Tau Medical Ltd

Inventors

• Arazi Lior
• Den Robert B
• Schmidt Michael
• Magen Ofer
• Kelson Itzhak
• Gat Amnon

Classifications

• A61N2005/1098

  Enhancing the effect of the particle by an injected agent or implanted device · CPC title

• A61N2005/1085

  characterised by the type of particles applied to the patient · CPC title

• A61N5/1027 Primary

  Interstitial radiation therapy · CPC title